I 

114TH CONGRESS 

1ST SESSION H. R. 2241 

To direct the Administrator of the United States Agency for International 

Development to submit to Congress a report on the development and 

use of global health innovations in the programs, projects, and activities 

of the Agency. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 5, 2015 

Mr. SIRES (for himself and Mr. DIAZ-BALART) introduced the following bill; 

which was referred to the Committee on Foreign Affairs 

A BILL 

To direct the Administrator of the United States Agency 

for International Development to submit to Congress a 

report on the development and use of global health innovations in the programs, projects, and activities of the 

Agency. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Global Health Innova5 tion Act of 2015’’. 


smartinez on DSK4TPTVN1PROD with BILLS
2 

•HR 2241 IH

1 SEC. 2. ANNUAL REPORT. 

2 (a) IN GENERAL.—Not later than 180 days after the 

3 date of the enactment of this Act, and annually thereafter, 

4 the Administrator of the United States Agency for Inter5 national Development shall submit to Congress a report 

6 on the development and use of global health innovations 

7 in the programs, projects, and activities of the Agency. 

8 (b) MATTERS TO BE INCLUDED.—The report re9 quired by subsection (a) shall include the following: 

10 (1) A description of— 

11 (A) the extent to which global health inno12 vations described in subsection (a) include 

13 drugs, diagnostics, devices, vaccines, electronic 

14 and mobile health technologies, and related be15 havior change and service delivery innovations; 

16 (B) how innovation has advanced the 

17 Agency’s commitments to achieving an HIV/ 

18 AIDS-free generation, ending preventable child 

19 and maternal deaths, and protecting commu20 nities from infectious diseases, as well as 

21 furthered by the Global Health Strategic 

22 Framework; 

23 (C) how goals are set for health product 

24 development in relation to the Agency’s health25 related goals and how progress and impact are 

26 measured towards those goals; 


smartinez on DSK4TPTVN1PROD with BILLS
3 

•HR 2241 IH

1 (D) how the Agency’s investments in inno2 vation relate to its stated goals; and 

3 (E) progress made towards health product 

4 development goals. 

5 (2) How the Agency both, independently and 

6 with partners, donors, and public-private partner7 ships, is— 

8 (A) leveraging United States investments 

9 to achieve greater impact in health innovation; 

10 (B) engaging in activities to develop, ad11 vance, and introduce affordable, available, and 

12 appropriate global health products; and 

13 (C) scaling up appropriate health innova14 tions in the development pipeline. 

15 (3) A description of collaboration and coordina16 tion with other Federal departments and agencies, 

17 including the Centers for Disease Control and Pre18 vention, in support of global health product develop19 ment, including a description of how the Agency is 

20 working to ensure critical gaps in product develop21 ment for global health are being filled. 

22 (4) A description of how the Agency is coordi23 nating and aligning global health innovation activi24 ties between the Global Development Lab, the CenVerDate Sep 11 2014 06:26 May 13, 2015 Jkt 049200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H2241.IH H2241

smartinez on DSK4TPTVN1PROD with BILLS
4 

•HR 2241 IH

1 ter for Accelerating Innovation and Impact, and the 

2 Bureau for Global Health. 

Æ 


smartinez on DSK4TPTVN1PROD with BILLS